The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer
- PMID: 16721360
- PMCID: PMC2361334
- DOI: 10.1038/sj.bjc.6603185
The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer
Abstract
There is increasing evidence that the presence of a systemic inflammatory response plays an important role in survival following curative resection for colorectal cancer. The present study evaluated the relationship between C-reactive protein concentrations and survival in a cohort of patients receiving adjuvant 5-fluorouracil (5-FU) chemotherapy following potentially curative resection for colorectal cancer. In all, 222 patients undergoing potentially curative resection for colorectal cancer were studied. Of these, 50 patients received adjuvant 5-FU-based chemotherapy. Circulating concentrations of C-reactive protein were measured prior to surgery. The minimum follow-up was 15 months; the median follow-up of the survivors was 38 months. During this period 61 patients died, 32 patients of their cancer and 29 of intercurrent disease. In those patients who did not receive adjuvant chemotherapy, age (P < 0.001), Dukes stage (P < 0.05) and an elevated C-reactive protein (P < 0.01) were significantly associated with survival. In those patients who did receive adjuvant chemotherapy, an elevated C-reactive protein concentration (P < 0.01) was significantly associated with survival. The presence of a systemic inflammatory response is an independent predictor of poor outcome in patients receiving adjuvant 5-FU-based chemotherapy following potentially curative resection for colorectal cancer.
Similar articles
-
Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.Oncology. 2006;70(5):366-77. doi: 10.1159/000098110. Epub 2006 Dec 15. Oncology. 2006. PMID: 17179731
-
Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.Anticancer Res. 2000 Nov-Dec;20(6C):4665-72. Anticancer Res. 2000. PMID: 11205198 Clinical Trial.
-
Systemic inflammatory response predicts survival following curative resection of colorectal cancer.Br J Surg. 2003 Feb;90(2):215-9. doi: 10.1002/bjs.4038. Br J Surg. 2003. PMID: 12555298
-
[Recent advances is surgical adjuvant chemotherapy for colorectal cancer].Gan To Kagaku Ryoho. 2000 Dec;27(14):2201-8. Gan To Kagaku Ryoho. 2000. PMID: 11142163 Review. Japanese.
-
[Current aspects of adjuvant and palliative chemotherapy in colorectal carcinoma].Praxis (Bern 1994). 1997 Sep 24;86(39):1510-6. Praxis (Bern 1994). 1997. PMID: 9411671 Review. German.
Cited by
-
The dynamic change of neutrophil to lymphocyte ratio can predict clinical outcome in stage I-III colon cancer.Sci Rep. 2018 Jun 21;8(1):9453. doi: 10.1038/s41598-018-27896-y. Sci Rep. 2018. PMID: 29930287 Free PMC article.
-
Quadruple Assessment of Colorectal Anastomosis after Laparoscopic Rectal Resection: A Retrospective Analysis of a Propensity-Matched Cohort.J Clin Med. 2024 Aug 27;13(17):5092. doi: 10.3390/jcm13175092. J Clin Med. 2024. PMID: 39274305 Free PMC article.
-
Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study.Cancer Epidemiol Biomarkers Prev. 2021 Jul;30(7):1349-1358. doi: 10.1158/1055-9965.EPI-20-1848. Epub 2021 May 10. Cancer Epidemiol Biomarkers Prev. 2021. PMID: 33972368 Free PMC article.
-
Post diagnosis diet quality and colorectal cancer survival in women.PLoS One. 2014 Dec 15;9(12):e115377. doi: 10.1371/journal.pone.0115377. eCollection 2014. PLoS One. 2014. PMID: 25506700 Free PMC article.
-
Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer.Exp Ther Med. 2011 Jan;2(1):95-101. doi: 10.3892/etm.2010.175. Epub 2010 Dec 2. Exp Ther Med. 2011. PMID: 22977476 Free PMC article.
References
-
- Andreyev HJ, Norman AR, Oates J, Cunningham D (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34: 503–509 - PubMed
-
- Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, Verweij J, Sparreboom A (2004) Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 10: 8341–8350 - PubMed
-
- Benson III AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22: 3408–3419 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials